Editorial · 30 Apr 2025
Conference abstractPublished 31 Aug 2018
Clinically useful deep learning models for risk stratification
Massachusetts Institute of Technology, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Cardiovascular disease and coronary heart disease (CHD) in particular remains a major cause of morbidity and mortality across the world. Over one-third of all deaths in patients over 35 can be attributed to some form of CHD and over 16 million people have CHD in the United States alone. Therefore, while tremendous progress has been made in the diagnosis and treatment of patients with CHD, significant challenges remain. Cardiovascular medicine is fortunate that insights into the appropriate care for patients with CHD are based on numerous large Randomized Controlled Clinical Trials (RCTs) over the past decades which have established contemporary treatment algorithms. Nevertheless, such insights are often not dispositive for an individual patient for several reasons. If a RCT enrolls a too heterogeneous population, it risks missing a treatment effect that is limited to a particular patient group based on comorbidities or genetic predisposition, for example. Even in a study that demonstrates the overall efficacy of a novel agent or strategy, certain signals of particular benefit (or risk) can be missed among the larger observations due to inadequate characterizations of individual characteristics. These observations demonstrate that it is not always clear how to apply the results of a given RCT to heterogeneous patient populations.Our work is guided by the hypothesis that the application of recently developed machine learning methods to large datasets, arising from observational studies, can facilitate the detection and understanding of the novel and complex interactions between patient characteristics, treatments and outcomes. In this talk I will describe a series of examples that demonstrate how complex machine learning methods can 1) improve our ability to identify high-risk patient subgroups, and, 2) discover novel treatment regimens that can reduce a patientâ??s risk of adverse future events. More generally, I will outline a set of criteria that can be used to judge the usefulness of any machine learning model that is intended to be used by the clinical community at large.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Commentary · 28 Feb 2025
Epileptic Seizure Detection Using a Transfer Entropy-based Causal Deep Learning Model
Conference abstract · 2023
Deep learning model for grading metastatic Epidural Spinal Cord Compression on staging CT
Research article · 2019
Machine Learning Approaches for Risk Stratification and Predictive Modeling of Asthma
Perspective · 28 Oct 2022
Clinical neurophysiological analysis on Deep brain stimulation in animal models
More from this journal
The newest in Neurological Disorders.
Commentary · 24 Feb 2026
Vertebrobasilar Dolichoectasia: A Meta-Analysis of Clinical Manifestations and Treatment Approaches
Commentary · 24 Feb 2026
Leveraging Multi-Dimensional Encoding in Single-Channel Haptic Feedback for Enhanced Two-Dimensional Control
Commentary · 24 Feb 2026
The Paradox of Seizure Frequency Reporting: Over counted, Underreported, and Its Clinical Implications
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalNeurological Disorders
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Collin Melveton Stultz”

